Novartis Pharmaceuticals: clinical-trial pipeline
Novartis Pharmaceuticals is the sponsor of 3,406 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 379 are not yet finished and 19 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Open trials379
Phase 2/3 and 31,056
Countries99
New in 90 days19
Trials by phase
| Phase | Trials |
|---|---|
| Phase 3 | 1,018 |
| Phase 2 | 814 |
| Phase 4 | 524 |
| Phase 1 | 475 |
| Not applicable | 400 |
| Phase 1/2 | 135 |
| Phase 2/3 | 38 |
| Early phase 1 | 2 |
Trials by status
| Status | Trials |
|---|---|
| Completed | 2,522 |
| Terminated | 395 |
| Recruiting | 177 |
| Active, not recruiting | 161 |
| Withdrawn or not authorised | 107 |
| Not yet recruiting | 41 |
| Suspended or halted | 3 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 948 |
| Cardiovascular | 529 |
| Immunology and rheumatology | 497 |
| Nephrology and urology | 335 |
| Respiratory | 308 |
| Metabolic and endocrine (diabetes, obesity) | 270 |
| Neurology | 266 |
| Dermatology | 230 |
| Rare and genetic diseases | 215 |
| Gastroenterology and liver | 211 |
| Infectious disease and vaccines | 178 |
| Ophthalmology | 166 |
Countries
| Country | Trials |
|---|---|
| United States | 1,672 |
| Germany | 1,255 |
| Spain | 849 |
| Italy | 781 |
| France | 766 |
| United Kingdom | 665 |
| Canada | 654 |
| Belgium | 528 |
| Japan | 501 |
| Netherlands | 472 |
| Australia | 458 |
| Switzerland | 423 |
| South Korea | 409 |
| Poland | 382 |
| Hungary | 373 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-10-23 | New trial posted | A clinical trial to learn about the safety of HJB647 in people with uncontrolled hyperten… |
| 2026-10-19 | New trial posted | A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With P… |
| 2026-10-09 | New trial posted | A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Ta… |
| 2026-10-06 | New trial posted | An open-label, single-arm, multicenter roll-over extension program (REP) to characterize… |
| 2026-10-02 | New trial posted | A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Se… |
| 2026-09-30 | New trial posted | A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Prim… |
| 2026-09-28 | New trial posted | A Study of Disease Modifying Therapy Use in Women With Multiple Sclerosis Before, During,… |
| 2026-09-28 | New trial posted | An External Control Arm Study Comparing Survival Among Metastatic Castration-Resistant Pr… |
| 2026-09-24 | New trial posted | A Study of Real-world Use and Effectiveness of Cytoreductive Strategies for the Treatment… |
| 2026-09-21 | New trial posted | Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With… |
| 2026-09-15 | New trial posted | A Real-World Study of Ofatumumab in Multiple Sclerosis Patients in Germany and Japan |
| 2026-09-11 | New trial posted | Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patien… |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT04980833 | Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectru… | Phase 2 | Active, not recruiting | Spain, France, Ireland, United States |
| NCT04058756 | Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combi… | Phase 1 | Active, not recruiting | Belgium, Canada, Switzerland, China +13 |
| NCT04657822 | Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizu… | Phase 4 | Active, not recruiting | Belgium, Brazil, Colombia, Germany +6 |
| 2023-507556-68-00 | A two-year, double-blind, randomized, multicenter, active controlled Core Phase study to evaluate the safety… | Phase 3 | Active, not recruiting | Germany, Spain, France, Romania +1 |
| NCT04104776 | A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas | Phase 1/2 | Recruiting | Spain, France, United Kingdom, Italy +3 |
| NCT02393625 | Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-sma… | Phase 1 | Active, not recruiting | Australia, Belgium, Canada, Spain +4 |
| NCT02934568 | Ribociclib (LEE011) Rollover Study for Continued Access | Phase 2 | Active, not recruiting | Germany, Spain, France, Singapore +2 |
| NCT06247995 | A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patie… | Phase 1/2 | Active, not recruiting | Australia, Canada, China, Germany +9 |
| 2024-510946-15-00 | ORACLE: A long-term follow-up study to evaluate the safety of GT005 in participants with geographic atrophy,… | Phase 1/2 | Active, not recruiting | Germany, Spain, France, Poland |
| NCT04557462 | A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/… | Phase 3 | Recruiting | Argentina, Australia, Belgium, Brazil +31 |
| NCT01872260 | Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer | Phase 1/2 | Active, not recruiting | Australia, Switzerland, Spain, France +4 |
| NCT06133972 | Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythem… | Phase 3 | Recruiting | Argentina, Australia, Bulgaria, Brazil +25 |
| NCT04971226 | A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP | Phase 3 | Active, not recruiting | Austria, Australia, Belgium, Bulgaria +25 |
| 2023-509834-20-00 | A phase II, open-label, single arm study to evaluate the safety, efficacy, and pharmacokinetics of twice dail… | Phase 2 | Active, not recruiting | Austria, Czechia, Germany, Italy +2 |
| NCT05622708 | A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondy… | Phase 4 | Active, not recruiting | Belgium, Brazil, Colombia, Czechia +13 |
| NCT05109728 | A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of C… | Phase 1 | Active, not recruiting | Switzerland, Spain, France, Portugal +1 |
| NCT05646381 | A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progressi… | Phase 2 | Recruiting | Austria, Belgium, Canada, Switzerland +11 |
| NCT04925479 | Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia | Phase 1/2 | Active, not recruiting | China, Germany, France, Greece +9 |
| NCT06444113 | Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis | Phase 4 | Not yet recruiting | Germany, France, United Kingdom, Italy +2 |
| NCT04747613 | Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Active, not recruiting | Brazil, China, Czechia, Germany +12 |
| NCT04641442 | Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Aut… | Phase 2 | Active, not recruiting | Czechia, Spain, France, United Kingdom +3 |
| NCT03040973 | Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatin… | Phase 2 | Active, not recruiting | Belgium, Canada, China, Germany +7 |
| NCT06331312 | Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR) | Phase 3 | Active, not recruiting | Argentina, Australia, Belgium, Brazil +18 |
| NCT05624749 | Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythe… | Phase 3 | Active, not recruiting | Argentina, Australia, Chile, Colombia +11 |
| NCT05222529 | Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Les… | Phase 2 | Recruiting | Bulgaria, Colombia, Spain, United Kingdom +4 |
Hiring for clinical development
Novartis Pharmaceuticals has 66 open jobs with a clinical, regulatory, safety, biostatistics or medical-affairs title on its own career sites.
Website: novartis.com. All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Novartis Pharmaceuticals clinical trials: 379 open, 1,056 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/novartis-com/, data as of 2026-10-25.